Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
PARSIPPANY, NJ, July 29, 2024 (GLOBE NEWSWIRE) — Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the undefined extension granted by Centers for Medicare & Medicaid Services (CMS) to Novitas, its Medicare Administrative Contractor (MAC).
Related news for (IDXG)
- Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
- Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results
- Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
- Interpace Biosciences Announces First Quarter 2024 Financial and Business Results